Combination effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and individual chemotherapeutics in non-small cell lung cancer (NSCLC) cells with and without sensitizing-EGFR mutations.
C. Tsai
Honoraria - AstraZeneca; Lilly; Pfizer; Roche
K. Chang
No relevant relationships to disclose
C. Chiu
No relevant relationships to disclose
S. Hsiao
No relevant relationships to disclose